Extended Data Fig. 9: The CrossMAb IgG ReconnAb neutralizes better than bivalent ACE2 (Fc-ACE2).
From: Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors
(A) Schematic depicting the protein design for Fc-tagged ACE2. Fc fusion was put C-terminal of the ACE2 ectodomain. (B) Neutralization of Fc-ACE2 against the same VOCs tested as in Fig.6 depicts weaker neutralization compared to the IgG ReconnAb. (C) a table of neutralizing potency of the IgG ReconnAb compared to Fc-ACE2 and the fold improvement for the IgG ReconnAb compared to Fc-ACE2.
